PL3218504T3 - Trójsegmentowe arenawirusy jako wektory szczepionkowe - Google Patents
Trójsegmentowe arenawirusy jako wektory szczepionkoweInfo
- Publication number
- PL3218504T3 PL3218504T3 PL15794900T PL15794900T PL3218504T3 PL 3218504 T3 PL3218504 T3 PL 3218504T3 PL 15794900 T PL15794900 T PL 15794900T PL 15794900 T PL15794900 T PL 15794900T PL 3218504 T3 PL3218504 T3 PL 3218504T3
- Authority
- PL
- Poland
- Prior art keywords
- tri
- vaccine vectors
- arenaviruses
- segmented
- segmented arenaviruses
- Prior art date
Links
- 241000712891 Arenavirus Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
- C12N2760/10062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
- C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079493P | 2014-11-13 | 2014-11-13 | |
| PCT/EP2015/076458 WO2016075250A1 (en) | 2014-11-13 | 2015-11-12 | Tri-segmented arenaviruses as vaccine vectors |
| EP15794900.9A EP3218504B1 (en) | 2014-11-13 | 2015-11-12 | Tri-segmented arenaviruses as vaccine vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3218504T3 true PL3218504T3 (pl) | 2021-02-08 |
Family
ID=54545130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15794900T PL3218504T3 (pl) | 2014-11-13 | 2015-11-12 | Trójsegmentowe arenawirusy jako wektory szczepionkowe |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10722564B2 (pl) |
| EP (2) | EP3218504B1 (pl) |
| JP (3) | JP6805139B2 (pl) |
| CN (1) | CN107223130A (pl) |
| AU (2) | AU2015345080B2 (pl) |
| CA (1) | CA2967720C (pl) |
| CY (1) | CY1123339T1 (pl) |
| DK (1) | DK3218504T3 (pl) |
| ES (1) | ES2811093T3 (pl) |
| HK (1) | HK1244034A1 (pl) |
| HR (1) | HRP20201684T1 (pl) |
| HU (1) | HUE051390T2 (pl) |
| LT (1) | LT3218504T (pl) |
| PL (1) | PL3218504T3 (pl) |
| PT (1) | PT3218504T (pl) |
| RS (1) | RS60937B1 (pl) |
| SI (1) | SI3218504T1 (pl) |
| WO (1) | WO2016075250A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2604695T (pt) | 2007-12-27 | 2022-12-07 | Univ Zuerich | Vetores de arenavírus defeituosos para a replicação |
| AU2014359276B2 (en) * | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
| PL3218504T3 (pl) | 2014-11-13 | 2021-02-08 | Université De Genève | Trójsegmentowe arenawirusy jako wektory szczepionkowe |
| EP3307308A2 (en) * | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| WO2018045029A1 (en) * | 2016-09-02 | 2018-03-08 | The United States Of America, As Represented By The Secretary Of The Army | Pan south american arenavirus live attenuated vaccine |
| HRP20221474T1 (hr) * | 2015-11-04 | 2023-01-06 | Hookipa Biotech Gmbh | Cjepiva protiv virusa hepatitisa b |
| HUE059589T2 (hu) * | 2015-11-12 | 2022-12-28 | Hookipa Biotech Gmbh | Arenavírus részecskék, mint rák elleni vakcinák |
| AU2017353443A1 (en) * | 2016-11-04 | 2019-05-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| CN110719788A (zh) * | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| CN108611310A (zh) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建 |
| CN108977434A (zh) * | 2018-07-03 | 2018-12-11 | 张罗 | 鼻腔脱落细胞rna的提取方法 |
| WO2020255023A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
| US11795210B2 (en) | 2019-07-16 | 2023-10-24 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| CN114555799A (zh) | 2019-09-30 | 2022-05-27 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| JP2023500928A (ja) | 2019-11-07 | 2023-01-11 | ユニベルシタト バーゼル | ベクターとしてのアレナウイルス |
| BR112022024404A2 (pt) | 2020-05-29 | 2023-02-07 | Hookipa Biotech Gmbh | Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus |
| WO2022159664A1 (en) * | 2021-01-22 | 2022-07-28 | Chan Zuckerberg Biohub, Inc. | Engineered multi-segmented rna viruses for large-scale combinatorial genetic screening |
| BR112023019365A2 (pt) | 2021-03-23 | 2023-12-26 | Hookipa Biotech Gmbh | Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit |
| WO2022238546A1 (en) | 2021-05-13 | 2022-11-17 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| TW202334403A (zh) | 2021-11-08 | 2023-09-01 | 奧地利商霍歐奇帕生物科技有限公司 | 作為癌症免疫療法之表現突變kras、突變癌症驅動基因或腫瘤相關抗原之經修飾的沙狀病毒顆粒 |
| CN114231562A (zh) * | 2021-12-15 | 2022-03-25 | 中国科学院武汉病毒研究所 | 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用 |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| PT2604695T (pt) * | 2007-12-27 | 2022-12-07 | Univ Zuerich | Vetores de arenavírus defeituosos para a replicação |
| GB201001726D0 (en) * | 2010-02-03 | 2010-03-24 | Univ St Andrews | Bunyavirus vaccine |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| EP3269387B1 (en) | 2012-01-24 | 2019-07-17 | Sanford Health | Polynucleotides and polypeptides for treating oncogenic viral polypeptide positive tumors |
| US9809801B2 (en) | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| AU2014359276B2 (en) | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
| WO2015183895A1 (en) | 2014-05-27 | 2015-12-03 | University Of Rochester | Novel arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| JP6875274B6 (ja) | 2014-09-22 | 2021-06-30 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ピチンデウイルスのリバースジェネティクス系及び使用方法 |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| PL3218504T3 (pl) | 2014-11-13 | 2021-02-08 | Université De Genève | Trójsegmentowe arenawirusy jako wektory szczepionkowe |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| US10849969B2 (en) | 2015-10-23 | 2020-12-01 | Institut Pasteur | Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity |
| HRP20221474T1 (hr) | 2015-11-04 | 2023-01-06 | Hookipa Biotech Gmbh | Cjepiva protiv virusa hepatitisa b |
| HUE059589T2 (hu) | 2015-11-12 | 2022-12-28 | Hookipa Biotech Gmbh | Arenavírus részecskék, mint rák elleni vakcinák |
| AU2017266738B2 (en) | 2016-05-18 | 2023-10-12 | Hookipa Biotech Gmbh | Tri-segmented Pichinde viruses as vaccine vectors |
| AU2017353443A1 (en) | 2016-11-04 | 2019-05-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| CN110719788A (zh) | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
-
2015
- 2015-11-12 PL PL15794900T patent/PL3218504T3/pl unknown
- 2015-11-12 DK DK15794900.9T patent/DK3218504T3/da active
- 2015-11-12 HU HUE15794900A patent/HUE051390T2/hu unknown
- 2015-11-12 LT LTEP15794900.9T patent/LT3218504T/lt unknown
- 2015-11-12 US US15/526,211 patent/US10722564B2/en active Active
- 2015-11-12 EP EP15794900.9A patent/EP3218504B1/en active Active
- 2015-11-12 AU AU2015345080A patent/AU2015345080B2/en active Active
- 2015-11-12 EP EP20184468.5A patent/EP3778903A1/en active Pending
- 2015-11-12 JP JP2017525893A patent/JP6805139B2/ja active Active
- 2015-11-12 WO PCT/EP2015/076458 patent/WO2016075250A1/en active Application Filing
- 2015-11-12 CN CN201580073235.6A patent/CN107223130A/zh active Pending
- 2015-11-12 RS RS20201251A patent/RS60937B1/sr unknown
- 2015-11-12 ES ES15794900T patent/ES2811093T3/es active Active
- 2015-11-12 SI SI201531397T patent/SI3218504T1/sl unknown
- 2015-11-12 PT PT157949009T patent/PT3218504T/pt unknown
- 2015-11-12 CA CA2967720A patent/CA2967720C/en active Active
-
2018
- 2018-03-15 HK HK18103615.9A patent/HK1244034A1/zh unknown
-
2020
- 2020-07-07 US US16/922,489 patent/US20210145950A1/en not_active Abandoned
- 2020-09-16 CY CY20201100879T patent/CY1123339T1/el unknown
- 2020-10-19 HR HRP20201684TT patent/HRP20201684T1/hr unknown
- 2020-12-03 JP JP2020201083A patent/JP2021045154A/ja active Pending
-
2022
- 2022-01-06 AU AU2022200061A patent/AU2022200061A1/en active Pending
-
2023
- 2023-01-05 JP JP2023000345A patent/JP2023036933A/ja active Pending
- 2023-11-13 US US18/507,584 patent/US20240082376A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS60937B1 (sr) | 2020-11-30 |
| JP6805139B2 (ja) | 2020-12-23 |
| JP2021045154A (ja) | 2021-03-25 |
| JP2017535267A (ja) | 2017-11-30 |
| ES2811093T3 (es) | 2021-03-10 |
| CA2967720C (en) | 2024-01-02 |
| US20240082376A1 (en) | 2024-03-14 |
| AU2015345080A1 (en) | 2017-06-01 |
| US20210145950A1 (en) | 2021-05-20 |
| HK1244034A1 (zh) | 2018-07-27 |
| EP3218504B1 (en) | 2020-07-22 |
| PT3218504T (pt) | 2020-09-24 |
| CA2967720A1 (en) | 2016-05-19 |
| HRP20201684T1 (hr) | 2020-12-25 |
| SI3218504T1 (sl) | 2020-11-30 |
| EP3778903A1 (en) | 2021-02-17 |
| CY1123339T1 (el) | 2021-12-31 |
| AU2022200061A1 (en) | 2022-02-03 |
| EP3218504A1 (en) | 2017-09-20 |
| DK3218504T3 (da) | 2020-10-19 |
| CN107223130A (zh) | 2017-09-29 |
| US20170319673A1 (en) | 2017-11-09 |
| HUE051390T2 (hu) | 2021-03-01 |
| WO2016075250A1 (en) | 2016-05-19 |
| JP2023036933A (ja) | 2023-03-14 |
| US10722564B2 (en) | 2020-07-28 |
| AU2015345080B2 (en) | 2022-01-27 |
| LT3218504T (lt) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244034A1 (zh) | 作為疫苗載體的三片段沙粒病毒 | |
| PL3207053T3 (pl) | Nowe peptydy immunogenne | |
| GB201403684D0 (en) | Vector | |
| GB201410971D0 (en) | Vaccine | |
| GB201518684D0 (en) | Vaccine | |
| GB201410907D0 (en) | No details | |
| PL3185899T3 (pl) | Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd | |
| GB201509578D0 (en) | Vectors | |
| GB201418216D0 (en) | No details | |
| IL248223A0 (en) | Compositions of vaccine | |
| GB201522132D0 (en) | Vaccine | |
| GB201616904D0 (en) | Vaccine | |
| IL247535A0 (en) | Fox-viral oncolytic vectors | |
| LT3237349T (lt) | Patobulintas biologinis rišiklis | |
| GB201503483D0 (en) | Novel Antimmicrobial Peptides | |
| LT3188755T (lt) | Vakcina | |
| GB201601250D0 (en) | No details present | |
| GB201410910D0 (en) | No details | |
| ZA201702925B (en) | New immunostimulatory compounds | |
| GB201417214D0 (en) | Vaccine | |
| GB201614387D0 (en) | Improved vaccines | |
| GB201603029D0 (en) | Vaccine | |
| GB201518917D0 (en) | Vaccination | |
| GB201406628D0 (en) | Vaccine | |
| GB201503266D0 (en) | Vaccination |